Notch signaling and its effector Hes1 regulate multiple cell fate choices in the developing pancreas, but few direct target genes are known. Here we use transcriptome analyses combined with chromatin immunoprecipitation with next-generation sequencing (ChIP-seq) to identify direct target genes of Hes1.
Introduction
Notch signaling plays a pivotal role in pancreas development by regulating progenitor proliferation and cell fate decisions and thus ensures the precise and timely regulation of the cell number of each lineage, which is ultimately crucial for proper organ function [1] . The juxtacrine Notch signaling pathway is characterized by signal sending from one cell via the DSL (Delta/Serrate/LAG-2)-family of ligands. In mammals four ligands (Dll1, Dll4, Jag1, and Jag2) are capable of transactivating Notch receptors on neighboring cells.
Transactivation involves ligand ubiquination catalyzed by Mib1, which is required for ligand endocytosis.
Ligand endocytosis is thought to exert a pulling force on Notch receptors that allow cleavage by ADAM10 and the γ-secretase complex [2] [3] [4] [5] . This leads to release of the Notch Intracellular domain (NICD), translocation to the nucleus for activation of transcription through the obligate DNA binding partner Rbpj and the co-activator Maml1. Prominent among pancreatic Notch target genes is Hes1, which encodes a transcriptional repressor of the Hairy and Enhancer-of-split (Hes)-family of bHLH proteins [6] .
The pancreatic buds evaginate from the primitive gut tube around E9.0 in mouse development and is comprised of multipotent progenitor cells (MPCs) that give rise to the entire pancreas epithelium. Dll1-induced Notch activity in the MPCs acts to limit early endocrine differentiation through Hes1-mediated repression of the proendocrine gene Neurog3 and to maintain normal MPC proliferation [6] [7] [8] [9] . Hes1 and Neurog3 proteins are typically detected in a mutually exclusive pattern and this is likely a reflection of the lateral inhibition feedback mechanism. Lateral inhibition posits that a trunk progenitor undergoing endocrine differentiation will express more Dll1 than its neighbors, leading to Notch activation, upregulation of Hes1, and repression of Neurog3 (and Dll1) in the neighboring cells, which consequently will remain in a progenitor state. However, while some aspects of Notch-mediated lateral inhibition are likely to operate in the pancreas the complete mechanism is likely to be more complicated [7, 10] . Indeed, recent work suggests that EGF signaling is involved in initiating the downregulation of Hes1 that leads to derepression of Neurog3 and endocrine differentiation [11] .
Beginning around E10, MPCs progressively segregate into acinar cell fated tip progenitors and duct/endocrine fated trunk progenitors that can be followed by the segregation of a set of molecular markers.
Initially, MPCs are marked by co-expression of several transcription factors whose expression later diverge to either the tip lineage (Ptf1a and Gata4) or the trunk lineage (Nkx6-1, Sox9, Hnf1β, Onecut1, and Gata6; reviewed in [12] ). These transcription factors engage in a complex gene regulatory network (GRN) whose wiring is likely to be dynamic and change over time. For example, Ptf1a is necessary for proper Nkx6-1 expression in MPCs whereas later it will repress Nkx6-1 to establish a Ptf1a + Gata4 + tip/acinar fate over a Nkx6-1 + Hnf1 + Sox9 + trunk/bipotent progenitor fate. Conversely, forced expression of Nkx6-1 in MPCs represses Ptf1a expression and tip fate [13, 14] . In addition to its early function as a suppressor of endocrine differentiation, Notch signaling is also important for proper allocation of tip and trunk fates. Forced expression of N1ICD prevents the cells from adopting a tip fate [13, 15, 16] and N1ICD has been suggested to act by directly activating Nkx6-1 expression [17] and to suppress Ptf1a expression and/or function indirectly via induction of Hes1 [18, 19] . Conversely, conditional Mib1 mutants that have compromised Notch ligand activity show a complete conversion of trunk cells to a tip fate and to a lesser degree the same phenotype is seen in conditional Hes1 mutants and after expression of dominant negative Maml1 [17, 20] .
Thus, forced expression of Ptf1a phenocopies Notch loss-of-function mutations and forced expression of Nkx6-1 phenocopies Notch gain-of-function mutations but exactly how Notch interfaces with the above mentioned GRN, and at how many nodes, remains unclear.
In the present study, we have identified direct target genes of Hes1 and examined gene expression changes and pancreatic cell fate choices regulated by Notch signaling. We found 354 Hes1 bound genes in 266-6 cells, a model of MPCs previously used to define Ptf1a target genes [14] . Most notable among these were genes important for tip/trunk segregation such as Ptf1a and Nkx6-1 as well as genes involved in regulating endocrine differentiation such as Insm1 and Dll4. Surprisingly, we find Hes1 to bind a large number of distal regulatory elements previously reported to bind Ptf1a, including a site in the Nkx6-1 gene. Notably, we find multiple Hes1 bound genes, including tip progenitor/acinar markers; Ptf1a, Gfi1, and Gata4, that are deregulated by treatment with DAPT, a γ-secretase inhibitor (GSI). Lastly, we find the gene Cbfa2t3, encoding a transcriptional corepressor, to be bound by Hes1 and upregulated in the explant models after loss of Notch/Hes1 function. Together, our data suggest that Notch signaling regulate tip/trunk patterning by Hes1-mediated repression of multiple tip/acinar-specific transcriptional regulators and uncover new molecular targets of Notch signaling that may be important for controlling cell fate choices in pancreas development. Figure 1C ). The heatmap shown in Figure 1D reveals Figure 1D ), but also display significantly upregulated expression of classic acinar markers including Rbpjl (11.0-fold), Cela1 (24.9-fold), Ptf1a (5.8-fold), Gata4 (3.4-fold), Gfi1 (7.4-fold) and Cpa2 (12.2-fold) as shown on the volcano plot in Supplemental Figure 2 [22] .
RESULTS

Transcriptomes of
GSEA found the acinar progenitors to be enriched for Myc target genes (Schumacher Myc Targets Up), which is reassuring since Myc is a known acinar marker [23] and accordingly its transcript is enriched in the YFP + acinar population. A second gene set, "Sotiriou Breast Cancer Grade 1 vs 3 Up", is mainly containing genes associated with cell cycle and proliferation in line with the marked proliferation seen in tip/acinar cells at this stage of development [24] . Also, we found "Zhang TLX targets 36hr Down" to be enriched, a gene-set containing genes down-regulated in neural stem cells after Nr2e1 knock-out (previously knowns as TLX), also including cell cycle and proliferation markers such as Mki67. Figure 2 . GSEA of the signatures enriched in the bipotent/trunk population compared to the endocrine precursors largely contained cell cycle and proliferation markers in gene sets such as "Gobert Oligodendrocyte Differentiation Up" and "Zhang Cell Cycle" (Sup. Figure 1C ) highlighting the proliferative differences between trunk cells and the post-mitotic endocrine precursors [25] . Together this data set provides a comprehensive gene expression atlas of distinct progenitor populations with different Hes1 expression profiles. In the following sections, we map additional data sets from Hes1 ChIP-seq experiments and microarray analyses of GSI treated explants onto this gene expression atlas, in order to define Hes1 target genes.
Hes1
Chromatin Immunoprecipitation in 266-6 cell line reveals potential direct target genes. To investigate the genome-wide binding of Hes1 to find direct target genes in the mouse pancreas, we performed chromatin immunoprecipitation with next generation sequencing (ChIP-seq) of Hes1 in the acinar carcinoma cell line 266-6. This cell line, derived from an Ela-SV40 large T transgenic mouse [26] is the best available model of mouse multipotent pancreas progenitor cells available with co-expression of Pdx1, Onecut1, Ptf1a, and Nkx6-1 [14] . We observed that Notch signaling is active in these cells and that they respond to γ-secretase inhibition by reduced N1-ICD and Hes1 protein levels ( Figure 4 ). We performed ChIP-seq of Hes1 and did peak calling using MACS2 and among two biological replicates we found 359 common peaks of which 1/3 were found to be in promoter regions within 2kb of the Transcription Start Site (TSS), 1/3 located in introns and exons and the remaining 1/3 in distal intergenic regions (Figure 2A and B).
De novo motif search on Hes1 peaks close to promoters using Homer found an extended motif GGCACGCGCC motif (Figure2C), encompassing the classical C-site (underlined) described for Hairy proteins [27] . The second most enriched motif is of the Foxa family although at a much lower frequency. De novo motif search at the Hes1-bound loci distal to promoters revealed a Foxa motif ( Figure 2D ), a Hoxrelated site similar to the Pdx1 binding site, an extended bHLH motif GGCACGTG containing the classical Hairy B-site motif (underlined, [27] ), Nuclear receptor (Tlx), a Gata motif, and another bHLH motif CAGCTG, corresponding to the most abundant Ptf1a-bound site in the developing spinal cord, which is also the preferred recognition sequence for Ascl1 and Atoh1 proteins [28] [29] [30] [31] . Figure 3) . Interestingly, Neurog2 which is not expressed in the pancreas but is a Hes1 target in neuronal stem cells and in mouse embryonic stem cells [32] was found bound, whereas we did not find the most prominent expected Hes1 target in the pancreas, Neurog3 [6, 33, 34] , emphasizing the limitations of the acinar cell-derived 266-6 cell line (see discussion). and the previously described direct Hes1 target, Gadd45g, involved in growth arrest [32] .
Ptf1a binds to the same genomic regions as
Serendipitously, we noted binding of Hes1 to one of two distal regulatory elements surrounding Nkx6-1 previously shown by Thompson and colleagues to be bound by Ptf1a ( Figure 3D ), which prompted us to assess Ptf1a enrichment on our Hes1 peaks from published Ptf1a ChIP-seq data also made in 266-6 cell line [14] . We found extensive Ptf1a binding on distal Hes1 peaks but rarely on promoters bound by Hes1 ( Figure   3C ), consistent with the previously reported preferential binding of Ptf1a to distal sites [36] and the above mentioned de novo motif finding analysis that identified the Ptf1a site CATCTG. In addition to Nkx6-1, examples of Hes1 and Ptf1a binding to the same locus includes the Hes1 locus where Ptf1a binds within one of three major Hes1 peaks, the Acvrl1, Dll4/GM14207, and Gfi1 loci, the latter which is bound in the promoter region (Sup. However, Foxa2 co-binding included more than Ptf1a co-bound sites and also included sites co-bound by Rbpj, but not Ptf1a and Rbpjl, suggesting that these may represent Notch response elements (Sup. Figure   7 ). Figure 4) . The robust upregulation of Neurog3 despite the variability in the wildtype DMSO samples confirms that Notch signalling is suppressed after 24h DAPT treatment.
Notch Inhibition Increases Expression of
We found 104 differentially expressed RefSeq-genes when comparing DAPT treated Neurog3-null and wildtype samples. As expected, endocrine genes (defined as highly expressed in the sorted E15.5 GFP + RFP + DBA +/− endocrine precursor populations) showed higher expression in the wildtype than Neurog3-null (Sup. Figure 5 ). All the islet hormone genes and Neurog3 were included in this cluster (Sup. Figure 4) .
When comparing DAPT and vehicle treated Neurog3-null explants, we found 233 upregulated and 65 downregulated genes, the latter including: Reg3b, Fgf6, Fgf20 and trunk/duct marker Spp1 (Osteopontin) ( Figure 4B and Sup. Figure 4) . We reasoned that the downregulated genes could be direct Notch target genes, but did not find Notch related signatures or Rbpj-motifs enriched by GSEA (data not shown), however more in-depth analysis could reveal a direct link to Notch target genes.
Remarkably, the genes upregulated in DAPT versus vehicle treated Neurog3-null explants, revealed several acinar cell markers, such as Ptf1a, Rbpjl, Cpa1 and Cpa2, which was also reflected in the heatmap of the corresponding genes mapped to the expression data from the E15.5 FACS sorted pancreas populations where the top genes are mostly expressed in the tip/acinar compartment ( Figure 4C ). However, comparing DAPT treated Neurog3-null versus wildtype, did not reveal tip/acinar genes to be upregulated ( Figure 4C and Sup. Figure 5 ), and we therefore conclude that the propensity to upregulate acinar genes upon Notch inhibition is not restricted to the Neurog3-null population per se. A previous report also noted increased acinar differentiation after DAPT treatment of E12.5 wildtype explants [37] . Lineage tracing experiments are necessary to fully assess whether it is trunk progenitors or MPCs that respond to DAPT by upregulating acinar markers in our setup.
Cbfa2t3, Ptf1a, Gfi1, Gata4 and Nkx6-1 are Neurog3-Independent Targets of Hes1
Next we compared genes bound by Hes1 in 266-6 cells with genes deregulated in the DAPT versus vehicle treated Neurog3-null explants and found 13 genes. Of these, only Tm4sf1 was downregulated with DAPT treatment, while the remaining 12 Hes1 bound, derepressed genes include both of the master regulators of tip/trunk patterning Nkx6-1 and Ptf1a, as well as other important transcriptional regulators such as Gata4, Gfi1, Bhlha15 and Cbfa2t3 ( Figure 4D) Surprisingly, the presumed early (DBA + ) and late (DBA − ) endocrine precursors did not exhibit any significant differences in their transcriptomes but were, as expected, very different from the trunk and tip populations.
They expressed the expected endocrine markers, and revealed a set of genes not previously reported to be enriched in the endocrine lineage. For the tip and trunk progenitors the differences were less pronounced, similar to observations by Benitez and co-workers [21] , however, both trunk and tip progenitors showed enrichment of the expected markers. With the advent of single cell RNA-sequencing we anticipate that gene expression atlases like this will be a valuable additional resource due to its greater depth of transcript detection.
To gain insight into the direct molecular targets of the Notch pathway we perform Hes1 ChIP-seq, which provided 359 high confidence peaks overlapping between two biological replicates. We detected the classically defined C-site motif CACGCG [27] by Homer de novo motif search, which also extended the motif to ggCACGCGcc, which was found on the majority of peaks near promoters. Notably, we detected binding to the Hes1 promoter, which in other systems enables an auto-repressive feedback loop necessary for the oscillatory expression of Hes1 [32, 46] . We found several Hes1 bound genes in the pancreas which were previously found in mouse embryonic stem cells by ChIP-on-chip analysis [32] , including Gadd45g, Neurog2, Ptf1a, Dll4 and Ascl1, revealing that Hes1 binds many of the same sites independent of cell type or tissue.
Surprisingly, we do not find Neurog3 among the Hes1 bound genes in the acinar carcinoma derived 266-6 cell line despite that Hes1 has been shown to regulate and bind Neurog3 in mouse pancreas and other tissues [6, 32, 34] . We speculate that the Neurog3 locus would be epigenetically closed in tip/acinar cells, and this might be the reason for the lack of Neurog3 binding, perhaps through DNA methylation of the CpG dinucleotide found in the Hes1 motif, which prevents binding [47] . In contrast, we would expect to find Hes1 binding to Neurog3 in any cell that has potential to become endocrine Neurog3 + such as embryonic stem cells, MPCs, trunk progenitors, bile ducts [19] , stomach and intestine [6, 48, 49] . Indeed, ChIP-seq for HES1
in human ES cells combined with mutational analysis reveals many genes in the endocrine lineage being bound and regulated by HES1 (see accompanying manuscript). Commitment to the endocrine lineage begins with a short, transient burst of expression of Neurog3 that brings on a cascade of transcription factors to regulate the differentiation to an endocrine hormone-producing cell that migrates from the duct epithelium to the islets of Langerhans. Several reports have shown that down-regulation of Notch signalling and consequently Hes1 allows de-repression of Neurog3 and commitment to the endocrine lineage [6, 8, 34] .
However, to assess Neurog3-independent transcriptional changes upon Notch inhibition we sought to mask the secondary effects of endocrine differentiation by using Neurog3-null mouse explants. Despite high variability in the DMSO treated wildtype explants we were able to verify that DAPT treatment for 24h was sufficient to upregulate Neurog3 and the lack of endocrine marker expression in the Neurog3-null, confirmed the validity of our setup. We found that Notch inhibition have the potential upregulate tip/acinar markers both in wildtype and Neurog3-null explants, which is in line with previous observations [37, 50] . Qu and colleagues also find upregulation of acinar markers as well as insulin upon DAPT treatment of wildtype explants [37] . However, in that study DAPT was present throughout the culture period, which precludes direct comparison to our data. Tamoxifen-based tracing of "failed" endocrine precursors in
Neurog3
CreERT/CreERT null-mutants, to duct and acinar cells before E12.5, but exclusively to duct cells after E12.5 [51, 52] , suggests that cells activating the Neurog3-promoter lose the ability to become acinar cells after E13. However, when treating our Neurog3-null explants with DAPT we observe upregulation of numerous tip/acinar-expressed genes, suggesting that the Neurog3 null cells at E12.5+3d explant culture do have the potential to become acinar. This is most likely explained by the delay in development that is consistently observed in explant systems [53] .
Among the acinar markers genes upregulated in the Neurog3-null with DAPT treatment are Ptf1a, Gata4, Bhlha15, and Gfi1, which we also found to be bound by Hes1 in our ChIP-seq data. We show that Notch signalling controls multiple tip/acinar transcription factors necessary for tip fate allocation and maturation of acinar cells via Hes1 binding directly, not only to Ptf1a, but also the novel Hes1 target gene Gata4, both of which are upregulated with DAPT treatment independently of Neurog3. Hes1 binding to Ptf1a has been suggested before [18, 19] , but has not previously been demonstrated by a ChIP-based assay. Ptf1a and Nkx6-1 are believed to be the main transcription factors driving tip/trunk patterning, acting in a mutually antagonistic fashion [13] . Notch signalling acts upstream of these transcription factors, but the exact mechanism remains incompletely understood. Constitutive Notch signalling in MPCs via Pdx1 promoterdriven N1-ICD misexpression, favours an Nkx6-1 + trunk fate [13] , while dnMaml1 mis-expression, as well as conditional Mib1-and Hes1-null mutations forces MPCs to adopt a tip fate [17, 20] . Notch has been
proposed to activate Nkx6-1 expression through direct binding of the NICD-Rbpj complex to a regulatory site in the Nkx6-1 gene, which may then subsequently directly repress Ptf1a expression [13, 17] . Conversely, Ptf1a has been proposed to repress Nkx6-1 indirectly. The data we present here adds to this picture by demonstrating that Hes1 can repress Ptf1a expression directly, possibly in cooperation with Nkx6-1 and by
suggesting that Hes1 and Ptf1a may act together to repress Nkx6-1 when MPCs initiate tip fate allocation.
Nkx6-1 may then later be maintained in a repressed state in tip cells by other, perhaps epigenetic, factors. Moreover, the relatively low level of Nkx6-1 expression in the trunk progenitors, compared to β-cells [54, 55] , may be explained by opposing inputs from NICD [17] and Hes1 (this study). Remarkably, our data suggest direct, Hes1-mediated repression of Gata4, Bhlha15, and Gfi1. Gata4 and Gata6 are both expressed in
MPCs and simultaneous loss of these genes in mice results in pancreas agenesis while loss of Gata4 alone causes deficiencies in acinar development [44, 56] . Although, Gfi1 is best known for its requirement for intestinal goblet cell differentiation, Gfi1 is also expressed in embryonic pancreas from E11.5 and becomes restricted to tip/acinar cells later in development and knockout of Gfi1 results in exocrine dysplasia through defects in centroacinar cells [42] . The direct repression of Ptf1a, Gata4, Bhlha15, and Gfi1 by Hes1 suggests that Notch signalling suppresses acinar differentiation and maturation through multiple repressive "handles".
The extensive overlap between Hes1 peaks and published Ptf1a ChIP-seq peaks on distal sites (>2 kb away from TSS) is remarkable in this context. By immunoprecipitation we showed that endogenous Ptf1a protein can pull down Hes1, extending previous observations with overexpressed, epitope-tagged proteins [57] . The trimeric Ptf1 complex includes Ptf1a, and E-protein, and Rbpj [58, 59] , which intriguingly also binds to the Hes1 promoter [36, 40, 60] . Our data showing Hes1 and Ptf1a binding to neighbouring sites at a large number of loci makes it tempting to speculate that they can be bound simultaneously to form a repressive complex providing a means to convert the transcriptional activator Ptf1 into a repressor as well as possible feedback loops to the Notch pathway.
Notably, we find the transcriptional repressor Cbfa2t3 (also known as Mtg16, Eto2 or Zmynd4) to be a Hes1 bound gene, which is upregulated upon Notch inhibition in the Neurog3-null explants. Based on the literature Cbfa2t3 appears to be involved in numerous aspects of Notch mediated cell fate choice and bHLH-induced lineage commitment. The Cbfa2t3 −/− mouse has defective crypt proliferation and goblet cell differentiation, which may also implicate another Hes1 target gene, Gfi1, identified here. However, its role in the pancreas has only been studied in Xenopus where it is downstream of Neurog3 and is necessary for differentiation to insulin producing cells, ostensibly by downregulating Neurog3 [41, [61] [62] [63] [64] . In neural progenitors Cbfa2t3 it interacts with Ascl1 and Neurog2 and forms a negative feedback loop that represses Ascl1 and Neurog2 and it might act similarly in the pancreas on Neurog3 [65] . Further investigations in the role of Cbfa2t3 are necessary to shed light on its putative role in pancreatic cell fate choices.
Taken together, we performed the first ChIP-seq on endogenous Hes1, observed substantial overlap with Ptf1a on distal elements and we find Notch signalling control acinar differentiation including acinar genes Ptf1a, Gata4, Gfi1 and trunk/endocrine gene Nkx6-1 to be bound and repressed by Hes1 in a Neurog3 independent manner. This shows the specific means by which Notch signalling is controlling key transcription factors and thereby cell fate choice.
Materials and Methods
Mouse lines
Hes1-EGFP, Neurog3-RFP, Neurog3 tTA , Ptf1a YFP/+ mouse lines were described previously [66] [67] [68] [69] . Animals were maintained in adherence to guidelines issued by the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (ETS 123).
E15.5 FACS sorted populations
Mice were genotyped for heterozygosity by qPCR compared to wildtype and known homozygous by testcrosses. qPCR was performed according to manufacturer's instructions using ROCHE UPL probes as below on a Lightcycler 480II and compared to control locus: Ubc Promoter. Washed in 10% FBS in PBS, spin as above and resuspended in 10%FBS in PBS + DAPI.
Fluorescence activated cell sorting was done on BD Bioscience ARIA II. For Hes1GFP mated with Neurog3-RFP, gating GFP+, then sorting GFP+DBA+, GFP+DBA+RFP+ and GFP+RFP+ as indicated in Figure 1 .
Sorting was done directly to RLT+ for RNA purification with MicroElute RNeasy Plus (Qiagen).
Ptf1aYFP/+ embryos were dissected and dissociated as above and sorted directly to RLT plus and purified with MicroElute RNeasy Plus (Qiagen).
Neurog3tTA explants E12.5+4d
Heterozygous crosses of Neurog3 tTA/+ were set up for timed matings and at E12.5 dorsal pancreata were dissected and adhered to fibronectin coated slides (BD Bioscience) in DMEM (Gibco) with 20% FBS.
Changed media once daily and 24h before harvest added 10µM DAPT (Sigma, D5942) or DMSO as vehicle control. Explants were harvested in RLT and purified with MicroElute RNeasy Plus (Qiagen).
Microarray of E15.5 FACS populations and Explants
Quality of the RNA was checked by Bioanalyser pico kit (Agilent) and using 35 ng total RNA was subjected to amplification and hybridisation was done using Low Input Quick Input Amp Kit (Agilent) and loaded onto
Mouse GE 8x 60k microarrays (Agilent). ChIP-sequencing bioinformatics analysis:
Mapped reads with Bowtie2 to mm10 and tracks for the IGV browser were made using DeepTools.
Peakfinding was performed using MACS2, subtracted Encode Blacklist and did de novo motif finding was done using Homer using 200 base pairs surrounding the summit of the peaks. Ptf1a, Rbpj, Rbpjl, and Foxa2 seq signal on Hes1 peaks was made using Deeptools Computematrix function, defining the promoter region as within 2kb of TSS. GREAT software (http://great.stanford.edu/public/html/) was used for database enrichments showed in Figure 2E . For all other annotations ChIP-seeeker was used [72] . IGV software was used for visualisation of ChIP-sequencing tracks.
Microarray gene expression data analysis:
Limma package was used for both microarray experiments as detailed in userguide for quality check, hierarchical clustering, MultiDimensional Scaling plot and to find differential expression. Visualised within R environment with packages ggplot, ggrepel, pheatmap, and Superheat package for heatmaps with kmeans clustering using WardD2 method when applicaple.
Gene set enrichment Analysis was done using GSEA Java application loading the microarray datasets and finding enrichment comparing to C2 database of MsigDB. For Neurog3tTA explant microarrays the data from E15.5 FACS population studies described above providing specific genes expressed in Acinar, Endocrine and trunk/duct progenitor cell types were uploaded as custom gene sets and compared alongside C2
database.
Figure Legends 
